The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Real-world data on the safety and efficacy of cilta-cel in patients with RRMM
|
Cilta-cel, a BCMA targeting CAR T-cell therapy, was approved by the EMA and the U.S. FDA in 2022 for patients with RRMM exposed to ≥3 and ≥4 prior lines of therapy, respectively.1 These approvals were based on results from the phase Ib/II CARTITUDE-1 trial (NCT03548207).1 The Multiple Myeloma Hub previously reported the interim and the final results from this trial. Briefly, ORR and sCR rates were 98% and 83%, respectively, and median PFS and OS were 34.9 months and not reached, respectively.1 A multicenter, retrospective analysis including 16 medical centers in the U.S. Multiple Myeloma Immunotherapy Consortium assessed the safety and efficacy of cita-cel in a real-world population of 236 patients with RRMM in the SOC setting.1 Results from this analysis were published in Blood by Sidana et al.1 |
| Key learnings |
| Despite 54% of the infused patients not meeting the eligibility criteria of the CARTITUDE-1 trial, cilta-cel therapy demonstrated high response rates, with an ORR and ≥CR rate of 89% and 70%, respectively. |
| After a median follow-up of 13 months from infusion, median PFS and OS was not reached, with a 12-month estimated PFS and OS rate of 68% and 82%, respectively. High baseline ferritin levels, high-risk cytogenetics, and EMD were associated with inferior survival outcomes. |
| CRS, ICANS, and DNT occurred in 75% (Grade ≥3, 5%), 14% (Grade ≥3, 4%), and 10% of patients, respectively. |
| With the exception of non-melanoma skin cancers, 5.5% of patients had SPMs; 1.3% of which were myeloid malignancies or acute leukemias. |
| These findings demonstrate the efficacy of cilta-cel in a heterogenous real-world population of patients with RRMM. Additionally, the results highlight the need for close monitoring to mitigate late complications and avoid neurotoxicity. |
Abbreviations: BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; cita-cel, ciltacabtagene autoleucel; CR, complete response; CRS, cytokine release syndrome; DNT, delayed neurotoxicity; EMA, European Medicines Agency; EMD, extramedullary disease; FDA, Food and Drug Administration; ICANS, immune effector cell-associated neurotoxicity syndrome; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma; sCR, stringent CR; SOC, standard of care; SPM, second primary malignancy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
